Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

Keros Therapeutics' stock has plummeted over 70% due to safety issues in its phase 2 PAH study, halting all trial arms. Learn more about KROS stock here.